Disease Domain | Count |
---|---|
Immune System Diseases | 5 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Bispecific antibody | 6 |
Unknown | 1 |
Mechanism CD8 inhibitors [+1] |
Active Org. Mozart Therapeutics, Inc.Startup |
Originator Org. Mozart Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism ICOS modulators [+1] |
Active Org. Mozart Therapeutics, Inc.Startup |
Originator Org. Mozart Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD39 inhibitors [+1] |
Active Org. Mozart Therapeutics, Inc.Startup |
Originator Org. Mozart Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2024 |
Sponsor / Collaborator Mozart Therapeutics, Inc.Startup |